Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Interferon-beta 1b (Betaseron) Clear all
Completed No phase listed Observational

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

NCT00468182
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon-beta 1b (Betaseron)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 28, 2026, 10:54 AM EDT
Completed No phase listed Observational

Betaseron Pregnancy Registry

NCT00317564
View directory record Official record
Conditions
Birth Defects, Pregnancy Complications, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 28, 2026, 10:54 AM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

NCT00273364
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 28, 2026, 10:54 AM EDT
Completed No phase listed Observational

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

NCT01158183
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BAY86-5046_Interferon-beta-1b
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Sep 28, 2026, 10:54 AM EDT
Completed No phase listed Observational

Therapy Optimization in Multiple Sclerosis (MS)

NCT00819000
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
Drug
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Swartz Creek, Michigan • Columbus, Ohio • Carnegie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

NCT00002299
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Interferon beta-1b, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:54 AM EDT
Completed No phase listed Observational

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

NCT00490906
View directory record Official record
Conditions
Multiple Sclerosis, Low Bone Density
Interventions
Copaxone, Interferon-beta 1a, Interferon-beta 1b
Drug
Lead sponsor
Nancy Hammond, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

NCT00811395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 4 Interventional

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

NCT00206648
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaferon/Betaseron
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

BEYOND Pilot Study

NCT00893217
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaseron (Interferon beta-1b, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2009 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

NCT00489489
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for Teriflunomide), Interferon-β
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 28, 2026, 10:54 AM EDT
Completed No phase listed Observational

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

NCT02652091
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

NCT00000695
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon beta-1b, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Interferon-beta (IFN-beta)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
21
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

NCT00459667
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 3 Interventional

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

NCT00099502
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2008 · Synced Sep 28, 2026, 10:54 AM EDT
Completed No phase listed Observational

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

NCT01031459
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Betaseron (Interferon beta-1b, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

RNF and Betaseron® Tolerability Study

NCT00428584
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions
New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications

NCT01834586
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Anesthetic Topical Adhesive Synera
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

NCT00235989
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta 1b (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 28, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Pulse ACTH vs. MP for MS

NCT01049451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTH, Methylprednisolone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 28, 2026, 10:54 AM EDT